LAMELLASOME™ Products in Development
LAMELLASOME™ Nucleic Acid PlatformThe potential of the LAMELLASOME™ Nucleic Acid Platform to assist in the transfer of a broad range of genetic material is demonstrated by the two lead products.
LAMELLASOME™ CF-NALAMELLASOME™ CF-NA is a LAMELLASOME™/plasmid treatment targeted at functional CFTR replacement therapy for Cystic Fibrosis. Lamellar has data to prove that LAMELLASOME™ CF-NA provides safe and effective delivery of functional plasmid to lungs in vivo, while avoiding gene therapy-associated immune response.
LAMELLASOME™ IPF-NALAMELLASOME™ IPF-NA is a LAMELLASOME™/microRNA product that is being developed for the treatment of idiopathic pulmonary fibrosis.
Lamellar has shown that the miR is safely and effectively delivered by LAMELLASOME™ and that it has a significant downstream antifibrotic effect, demonstrated as a marked reduction in IPF biomarkers. All transfected cells demonstrated high transfection, high cell viability and maintenance of cell phenotype.
Strategic out-licensing, co-development and partnering
Safe and effective delivery is clearly a challenge for many types of active agent nucleic acids that are in development.
Lamellar are keen to explore potential opportunities for collaboration with organisations seeking improved delivery of their active agent nucleic acid as well as companies capable of taking our lead products through clinical development.